drug · antibody drug conjugate

ZYNLONTA

updated 2mo ago

/ LON-kas-TUK-si-mab /

by $ADCT ADC Therapeutics SA🔗 ChEMBL

community read0 votes

Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 5 investigational indications.

targets

B-lymphocyte antigen CD19

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

ZYNLONTA

trade names

Zynlonta

generic

LONCASTUXIMAB TESIRINE-LPYL

MOA

12.1 Mechanism of Action Loncastuximab tesirine-lpyl is an antibody-drug conjugate (ADC) targeting CD19. The monoclonal IgG1 kappa antibody component binds to human CD19, a transmembrane protein expressed on the surface of cells of B-lineage origin. The small molecule component is SG3199, a PBD dimer and alkylating agent. Upon binding to CD19, loncastuximab tesirine-lpyl is internalized followed by release of SG3199 via proteolytic cleavage. The released SG3199 binds to the DNA minor groove and forms highly cytotoxic DNA interstrand crosslinks, subsequently inducing cell death. Loncastuximab tesirine-lpyl had anticancer activity in animal models of lymphoma.

indication

1 INDICATIONS AND USAGE ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ZYNLONTA is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. ( 1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1 )

ZYNLONTA

targets

all catalysts(0)

News(0)

Report a data issue

🐶 often sniffed alongside

comments(0)